Eltrombopag, is a thrombopoietin receptor agonist is used to increase the number of platelets sufficient to decrease the risk of bleeding in thrombocytopenia patient and also allow treatment with interferon and ribavirin in people suffering with Hepatitis C. It is not used to increase platelets to a normal level. Eltrombopag should not be used to treat people having low numbers of platelets in patients other than immune thrombocytopenia or hepatitis C patients. Eltrombopag is thrombopoietin receptor agonists and works by creating the cells in the bone marrow to produce more platelets. It is an orally bioavailable molecule with the potential to benefit patients with a wide range of thrombocytopenias including thrombocytopenia secondary to chronic liver disease. Chronic hepatitis C is a public health problem all over the world. Eltrombopag can be a solution for many patients as it will allow for antiviral therapy and getting a sustained virological response, but requires proper monitoring to prevent possible bone marrow complications or liver failure occurrence. Eltrombopag, and thrombopoietin can be used effectively in treatment of thrombocytopenia and hepatitis C.
Biography of author(s)
Sachin Kumar Jain
Associate Professor in the Department of Pharmacognosy, IPS Academy College of Pharmacy, Indore MP India affiliated to RGPV technical University Bhopal MP India.
Read full article: http://bp.bookpi.org/index.php/bpi/catalog/view/23/44/129-1
View Volume: https://doi.org/10.9734/bpi/ctmmr/v2
Book Publisher International 